

- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
- Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. *Cancer* 2004;101:281–288.
- Frisch M, Melbye M, Moller H. Trends in incidence of anal cancer in Denmark. *BMJ* 1993;306:419–422.
- Grolich AE, Poynten IM, Machalek DA, et al. The epidemiology of anal cancer. *Sex Health* 2012;9:504–508.
- Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. *Lancet Oncol* 2012;13:487–500.
- Lawton MD, Nathan M, Asboe D. HPV vaccination to prevent anal cancer in men who have sex with men. *Sex Transm Infect* 2013;89:342–343.
- Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. *N Engl J Med* 1997;337:1350–1358.
- Goodman MT, Shvetsov YB, McDuffie K, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. *J Infect Dis* 2010;201:1331–1339.
- Diamond C, Taylor TH, Aboumarad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. *Sex Transm Dis* 2005;32:314–320.
- Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. *AIDS* 2010;24:535–543.
- Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst* 2011;103:753–762.
- Shiels MS, Pfeiffer RM, Chaturvedi AK, et al. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. *J Natl Cancer Inst* 2012;104:1591–1598.
- Rubinstein P, Sreenivasappa S, Gupta S, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for invasive anal carcinoma in HIV positive patients receiving highly active anti-retroviral therapy versus non-HIV patients. (ASCO 2012). *J Clin Oncol* 2012;30 (supplement).
- Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. *Cancer* 2004;101:270–280.
- Grolich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet* 2007;370:59–67.
- Berry JM, Jay N, Cranston RD, et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. *Int J Cancer* 2014;134:1147–1155.
- Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. *J Acquir Immune Defic Syndr Hum Retroviro* 1998;17:314–319.
- Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. *Br J Dermatol* 2010;162:1269–1277.
- Jay N, Berry JM, Hogeboom CJ, et al. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. *Dis Colon Rectum* 1997;40:919–928.
- Gimenez F, Costa-e-Silva IT, Daumas A, et al. The value of high-resolution anoscopy in the diagnosis of anal cancer precursor lesions in HIV-positive patients. *Arq Gastroenterol* 2011;48:136–145.
- Fox PA, Nathan M, Francis N, et al. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. *AIDS* 2010;24:2331–2335.
- Richel O, Wieland U, de Vries HJ, et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. *Br J Dermatol* 2010;163:1301–1307.
- Singh JC, Kuohung V, Palefsky JM. Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIV-negative men who have sex with men. *J Acquir Immune Defic Syndr* 2009;52:474–479.
- Macaya A, Munoz-Santos C, Balaguer A, et al. Interventions for anal canal intraepithelial neoplasia. *Cochrane Database Syst Rev* 2012;12:CD009244.
- FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007;356:1915–1927.
- Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. *Lancet* 2007;369:2161–2170.
- Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. *Br J Cancer* 2006;95:1459–1466.
- Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med* 2011;365:1576–1585.
- Fenger C, Frisch M, Marti MC, et al. Tumors of the anal canal. In: Hamilton SR, Aaltonen LA, eds. *World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System*. Lyon, France: IARC Press, 2000:145–155.
- Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. *Br J Surg* 2005;92:1133–1136.
- Glynn-Jones R, Renehan A. Current treatment of anal squamous cell carcinoma. *Hematol Oncol Clin North Am* 2012;26:1315–1350.
- Lemarchand N, Tanne F, Aubert M, et al. Is routine pathologic evaluation of hemorrhoidectomy specimens necessary? *Gastroenterol Clin Biol* 2004;28:659–661.
- Kreuter A, Brockmeyer NH, Hochdorfer B, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. *J Am Acad Dermatol* 2005;52:603–608.
- Wiefeldt ED, Thiele J. Malignancies of the anal margin and perianal skin. *Clin Colon Rectal Surg* 2009;22:127–135.
- Tehrani S, Treglia G, Krag DN, et al. Sentinel node mapping in anal cancer: systematic review and meta-analysis. *J Gastrointest Liver Dis* 2013;22:321–328.
- Sveistrup J, Loft A, Berthelsen AK, et al. Positron emission tomography/computed tomography in the staging and treatment of anal cancer. *Int J Radiat Oncol Biol Phys* 2012;83:134–141.
- Wells IT, Fox BM. PET/CT in anal cancer—is it worth doing? *Clin Radiol* 2012;67:535–540.
- Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. *Int J Colorectal Dis* 2011;26:201–210.
- Day FL, Link E, Ngan S, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. *Br J Cancer* 2011;105:498–504.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology—Anal Carcinoma (Version 2.2014). http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed June 20, 2014.
- Touboul E, Schlienger M, Buffat L, et al. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. *Cancer* 1994;73:1569–1579.
- Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). *Cancer* 2010;116:4007–4013.
- Bartelink H, Roelofs F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997;15:2040–2049.
- Glynn-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT 1). *Cancer* 2013;119:748–755.
- Cummings BJ, Keane TJ, O'Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. *Int J Radiat Oncol Biol Phys* 1991;21:1115–1125.
- Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. *Int J Radiat Oncol Biol Phys* 2007;68:794–800.
- Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol* 1996;14:2527–2539.
- Schlienger M, Krzisch C, Pene F, et al. Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases. *Int J Radiat Oncol Biol Phys* 1989;17:1141–1151.
- Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. *Eur J Cancer* 2008;44:946–953.
- Lampejo T, Kavanagh D, Clark J, et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. *Br J Cancer* 2010;103:1858–1869.
- Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. *Cancer Metastasis Rev* 1995;14:3–15.
- Wong CS, Tsao MS, Sharma V, et al. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 1999;45:309–314.
- Tanum G, Holm R. Anal carcinoma: a clinical approach to p53 and RB gene proteins. *Oncology* 1996;53:369–373.
- Indinnimeo M, Cicchini C, Stazi A, et al. Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma. *J Exp Clin Cancer Res* 1999;18:47–52.
- Ajani JA, Wang X, Izzo JG, et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. *Dig Dis Sci* 2010;55:1098–1105.
- Bonin SR, Pajak TF, Russell AH, et al. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. *Radiation Therapy Oncology Group*. *Cancer* 1999;85:1226–1233.

57. Allal AS, Waelchli L, Brundler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. *Clin Cancer Res* 2003;9:6489-6496.
58. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. *Cell* 1993;75:817-825.
59. Holm R, Skovlund E, Skomedal H, et al. Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas. *Histopathology* 2001;39:43-49.
60. Nilsson PJ, Lenander C, Rubio C, et al. Prognostic significance of Cyclin A in epidermoid anal cancer. *Oncol Rep* 2006;16:443-449.
61. Steele SR, Varma MG, Melton GB, et al. Practice parameters for anal squamous neoplasms. *Dis Colon Rectum* 2012;55:735-749.
62. Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. *Cancer* 1984;54:114-125.
63. Singh R, Nime F, Mittelman A. Malignant epithelial tumors of the anal canal. *Cancer* 1981;48:411-415.
64. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. *Dis Colon Rectum* 1974;17:354-356.
65. Nigro ND, Vaitkevicius VK, Brooker T, et al. Combined therapy for cancer of the anal canal. *Dis Colon Rectum* 1981;24:73-75.
66. Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. *Cancer* 1983;51:1826-1829.
67. Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. *Am J Med* 1985;78:211-215.
68. Meeker WR Jr, Sickle-Santanello BJ, Philpott G, et al. Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal. *Cancer* 1986;57:525-529.
69. Michaelson RA, Magill GB, Quan SH, et al. Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma. *Cancer* 1983;51:390-395.
70. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. *Lancet* 1996;348:1049-1054.
71. Northover J, Glynn-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). *Br J Cancer* 2010;102:1123-1128.
72. Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). *J Clin Oncol* 2008;26:3229-3234.
73. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008;299:1914-1921.
74. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol* 2012;30:4344-4351.
75. James RD, Glynn-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. *Lancet Oncol* 2013;14:516-524.
76. Peiffert D, Tourmier-Rangard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol* 2012;30:1941-1948.
77. Ajani JA, Winter KA, Gunderson LL, et al. Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. *J Clin Oncol* 2006;24:180s.
78. Gunderson LL, Winter KA, Ajani JA, et al. Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact of disease-free, overall and colostomy-free survival (abstract). *Int J Radiat Oncol Biol Phys* 2006;66:S24.
79. Garg M, Lee JY, Kachnic L, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV positive (AMCO45) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. *J Clin Oncol* 2012;30:abstr 4030.
80. Deutsch E, Lemanski C, Paris E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. *J Clin Oncol* 2011;29:abstr 4098.
81. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. *J Clin Oncol* 2007;25:4581-4586.
82. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. *Int J Radiat Oncol Biol Phys* 2010;78:1413-1419.
83. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. *J Clin Oncol* 2010;28:5061-5066.
84. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. *Int J Radiat Oncol Biol Phys* 2012;82:153-158.
85. Kachnic IA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 2013;86:27-33.
86. Tanum G. Treatment of relapsing anal carcinoma. *Acta Oncol* 1993;32:33-35.
87. Glynn-Jones R, James R, Meadows H, et al, eds. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. Paper presented at: 2012 ASCO Annual Meeting; 2012; Chicago, IL.
88. Sebag-Montefiore D, James R, Meadows H, et al. The pattern and timing of disease recurrence in cancer of the anus: mature results from the NCRI ACT II trial. *J Clin Oncol*. 2012;30. 2012 ASCO Annual Meeting.
89. Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. *Int J Radiat Oncol Biol Phys* 2006;66:206-211.
90. Cleator S, Fife K, Nelson M, et al. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. *Eur J Cancer* 2000;36:754-758.
91. Peddada AV, Smith DE, Rao AR, et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 1997;37:1101-1105.
92. Oehler-Janne C, Seifert B, Lutolf UM, et al. Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. *Radiat Oncol* 2006;1:29.
93. Kauh J, Koshy M, Gunthel C, et al. Management of anal cancer in the HIV-positive population. *Oncology (Williston Park)* 2005;19:1634-1638.
94. Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. *Int J Radiat Oncol Biol Phys* 1999;44:127-131.
95. Place RJ, Gregorcyk SC, Huber PJ, et al. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. *Dis Colon Rectum* 2001;44:506-512.
96. Garg M, Lee JY, Kachnic L, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMCO45) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. 2012 ASCO Annual Meeting.
97. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. *Dis Colon Rectum* 2005;48:1176-1181.
98. Munoz-Bongrand N, Poghossyan T, Zohar S, et al. Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. *Dis Colon Rectum* 2011;54:729-735.
99. Seo Y, Kinsella MT, Reynolds HL, et al. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. *Int J Radiat Oncol Biol Phys* 2009;75:143-149.
100. Oehler-Janne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. *J Clin Oncol* 2008;26:2550-2557.
101. Sunesen KG, Buntzen S, Tei T, et al. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. *Ann Surg Oncol* 2009;16:68-77.
102. Akbari RP, Paty PB, Guillem JG, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. *Dis Colon Rectum* 2004;47:1136-1144.
103. Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. *Ann Surg Oncol* 2007;14:2780-2789.
104. Correa JH, Castro LS, Kesley R, et al. Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. *J Surg Oncol* 2013;107:486-492.
105. Nilsson PJ, Svensson C, Goldman S, et al. Salvage abdominoperineal resection in anal epidermoid cancer. *Br J Surg* 2002;89:1425-1429.
106. Ghouti L, Houvenaeghel G, Moutardier V, et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. *Dis Colon Rectum* 2005;48:16-22.
107. Renehan AG, Saunders MP, Schofield PF, et al. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. *Br J Surg* 2005;92:605-614.
108. Lefevre JH, Parc Y, Kerneis S, et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneous flap on survival, recurrence, morbidity, and wound healing. *Ann Surg* 2009;250:707-711.
109. Ferenschild FT, Vermaas M, Hofer SO, et al. Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. *World J Surg* 2005;29:1452-1457.
110. Eeson G, Foo M, Harrow S, et al. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. *Am J Surg* 2011;201:628-633.

111. Lefevre JH, Corte H, Tiret E, et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. *Ann Surg Oncol* 2012;19:4186–4192.
112. Faivre C, Rougier P, Ducreux M, et al. [5-fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer]. *Bull Cancer* 1999;86:861–865.
113. Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. *Am J Clin Oncol* 1993;16:536–540.
114. Khater R, Frenay M, Bourry J, et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. *Cancer Treat Rep* 1986;70:1345–1346.
115. Ajani JA, Carrasco CH, Jackson DE, et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. *Am J Med* 1989;87:221–224.
116. Greenall MJ, Quan SH, Stearns MW, et al. Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. *Am J Surg* 1985;149:95–101.
117. Dewdney A, Rao S. Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? *ISRN Oncol* 2012;2012:756591.
118. Wilking N, Petrelli N, Herrera L, et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. *Cancer Chemother Pharmacol* 1985;15:300–302.
119. Hainsworth JD, Burris HA 3rd, Meluch AA, et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. *Cancer* 2001;92:642–649.
120. Jhaver M, Mani S, Lefkopoulou M, et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. *Invest New Drugs* 2006;24:447–454.
121. Eng C, Rogers J, Chang GJ, et al. Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. *J Clin Oncol* 2012;30:abstr 4060.
122. Evans TR, Mansi JL, Glees JP. Response of metastatic anal carcinoma to single agent carboplatin. *Clin Oncol (R Coll Radiol)* 1993;5:57–58.
123. Zimm S, Wampler GL. Response of metastatic cloacogenic carcinoma to treatment with semustine. *Cancer* 1981;48:2575–2576.
124. Grifaichi F, Padovani A, Romeo F, et al. Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. *Tumori* 2001;87:58–59.
125. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2006;354:567–578.
126. De Dosso S, Martin V, Zanellato E, et al. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. *Tumori* 2010;96:627–628.
127. Lukan N, Strobel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. *Oncology* 2009;77:293–299.
128. Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. *Dis Colon Rectum* 2007;50:395–398.
129. Pawlik TM, Gleisner AL, Bauer TW, et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. *Ann Surg Oncol* 2007;14:2807–2816.
130. Hodges JC, Das P, Eng C, et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. *Int J Radiat Oncol Biol Phys* 2009;75:791–794.
131. Charnley N, Choudhury A, Chesser P, et al. Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. *Br J Cancer* 2005;92:1221–1225.
132. Cutuli B, Fenton J, Labib A, et al. Anal margin carcinoma: 21 cases treated at the Institut Curie by exclusive conservative radiotherapy. *Radiother Oncol* 1988;11:1–6.
133. Peiffert D, Bey P, Pernot M, et al. Conservative treatment by irradiation of epidermoid carcinomas of the anal margin. *Int J Radiat Oncol Biol Phys* 1997;39:57–66.
134. Chawla AK, Willett CG. Squamous cell carcinoma of the anal canal and anal margin. *Hematol Oncol Clin North Am* 2001;15:321–344.
135. Morson B. The pathology and results of treatment of squamous cell carcinoma of the anal canal and anal margin. *J R Soc Med* 1960;53.
136. Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. *Dis Colon Rectum* 1992;35:422–429.
137. Chapet O, Gerard JP, Mornex F, et al. Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience. *Int J Colorectal Dis* 2007;22:191–199.
138. Khanfir K, Ozsahin M, Bieri S, et al. Patterns of failure and outcome in patients with carcinoma of the anal margin. *Ann Surg Oncol* 2008;15:1092–1098.
139. Balamucki CJ, Zlotnicki RA, Rout WR, et al. Squamous cell carcinoma of the anal margin: the university of Florida experience. *Am J Clin Oncol* 2011;34:406–410.
140. Deans GT, McAleer JJ, Spence RA. Malignant anal tumours. *Br J Surg* 1994;81:500–508.
141. Chia CS, Chew MH, Chau YP, et al. Adenocarcinoma of the anal transitional zone after double stapled ileal pouch-anal anastomosis for ulcerative colitis. *Colorectal Dis* 2008;10:621–623.
142. Ota H, Yamazaki K, Endoh W, et al. Adenocarcinoma arising below an ileoanal anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case. *Surg Today* 2007;37:596–599.
143. Wong NA, Shirazi T, Hamer-Hodges DW, et al. Adenocarcinoma arising within a Crohn's-related anorectal fistula: a form of anal gland carcinoma? *Histopathology* 2002;40:302–304.
144. Belkacemi Y, Berger C, Poortmans P, et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. *Int J Radiat Oncol Biol Phys* 2003;56:1274–1283.
145. Kounalakis N, Artinyan A, Smith D, et al. Abdominal perineal resection improves survival for nonmetastatic adenocarcinoma of the anal canal. *Ann Surg Oncol* 2009;16:1310–1315.
146. Papagikos M, Crane CH, Skibber J, et al. Chemoradiation for adenocarcinoma of the anus. *Int J Radiat Oncol Biol Phys* 2003;55:669–678.
147. Weinstock MA. Epidemiology and prognosis of anorectal melanoma. *Gastroenterology* 1993;104:174–178.
148. Iversen K, Robins RE. Mucosal malignant melanomas. *Am J Surg* 1980;139:660–664.
149. Wanebo HJ, Woodruff JM, Farr GH, et al. Anorectal melanoma. *Cancer* 1981;47:1891–1900.
150. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. *Dis Colon Rectum* 1995;38:146–151.
151. Quan SH, White JE, Deddish MR. Malignant melanoma of the anorectum. *Dis Colon Rectum* 1959;2:275–283.
152. Metildi C, McLemore EC, Tran T, et al. Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry. *Am Surg* 2013;79:1068–1074.
153. Slingluff CL Jr, Seigler HF. Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. *Ann Plast Surg* 1992;28:85–88.
154. Kiran R, Rottoli M, Pokala N, et al. Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database. *Dis Colon Rectum* 2010;53:402.
155. Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. *Br J Surg* 2010;97:98–103.
156. Kanaan Z, Mulhall A, Mahid S, et al. A systematic review of prognosis and therapy of anal malignant melanoma: a plea for more precise reporting of location and thickness. *Am Surg* 2012;78:28–35.
157. Ishizone S, Koide N, Karasawa F, et al. Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases. *Int J Colorectal Dis* 2008;23:1257–1262.
158. Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. *J Clin Oncol* 2002;20:4555–4558.